News | June 25, 2024
Venus Remedies clinches WHO-backed PAHO tender
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Renews GMP certifications for India and Malaysia sites
The company will now explore a buyer for its manufacturing site and exit in due course
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
